U.S. Markets open in 14 hrs, 53 mins
| Symbol | Value | Change | Percentage Change |
|---|---|---|---|
| DJIA | 11,430.21 | 12.78 | 0.11% |
| NASDAQ | 2,380.38 | -8.70 | -0.36% |
| S&P 500 | 1,277.72 | 3.18 | 0.25% |
| Day Low 12:25 PM EDT | 86.17 | |
|---|---|---|
| Day High 09:30 AM EDT | 90.30 |
|
| Range | 4.13 | |
| Volume | 1.21 M | |
| 30-Day Avg. Vol. | 1.02 M |
|
| Difference | 19.36% | |
| Market Cap. | 3.42 B | |
| Change | -67.68 M | |
| Shares Out. | 38.41 M | |
| Percent Traded | 3.13% | |
| Revenue | 72.04 M | |
| Earnings | -92.29 M | |
| EPS (TTM) | -0.91 |
| 52-Wk Low 3/17/08 | 49.26 | |
|---|---|---|
| 52-Wk High 8/14/08 | 95.91 |
|
| Range | 46.65 | |
| Prev. Close 8/20/08 | 89.74 | |
| Today's Open | 89.26 | |
| Change | -0.53% | |
| Dividend (TTM) | 0.00 | |
| Div. Yield (TTM) | 0.00% |
|
| Beta | 0.9771 | |
| P/E Ratio (TTM) | — | |
| P/E Ratio (Fwd.) | 121.00 |
Alexion Pharmaceuticals can't suppress its enthusiasm for treating immune functions gone awry. The firm develops drugs that inhibit certain immune system functions that cause autoimmune disorders, cancers, ... View Full Description
| Earnings/Share(EPS) | Estimate | Actual | Difference |
|---|---|---|---|
| 2 Quarters Ago | -0.428 3/31/08 | -0.11 3/31/08 |
0.318
Beat
|
| Last Quarter | -0.137 6/30/08 | 0.06 6/30/08 |
0.197
Beat
|
| Quarterly - 06/30/2008 | Annual - 2007 | |
|---|---|---|
| Total Revenue | 59.56 M | 72.04 M |
| Gross Profit | 52.42 M | 65.34 M |
| Operating Income | 2.68 M | -99.76 M |
| Net Income | 2.37 M | -92.29 M |
Real-Time Quote
